期刊文献+

乳腺癌分子亚型与MRI表现的相关性 被引量:6

Correlation between molecular subtypes of breast cancer and MRI features
暂未订购
导出
摘要 目的探讨不同分子亚型乳腺癌与MRI表现的相关性。方法回顾性分析121例经手术病理证实的乳腺癌患者,根据雌激素受体(ER)、孕激素受体(PR)、人表皮生长因子受体(HER-2)表达状态,将乳腺癌分为HER-2过表达型、Luminal A型、Luminal B型和三阴性型,观察不同亚型乳腺癌MRI表现及其与分子亚型的相关性。结果 4种分子亚型乳腺癌T1WI多呈稍低信号[HER-2过表达型:68.00%(17/25),Luminal A型:66.67%(38/57),Luminal B型:76.19%(16/21),三阴性型55.56%(10/18)];HER-2过表达型多呈非肿块样强化[84.00%(21/25)],Luminal A型多呈不均匀强化[75.44%(43/57)],Luminal B型和三阴性型多呈环形强化[52.38%(11/21)、83.33%(15/18)];HER-2过表达型、Luminal B型和三阴性型时间-信号强度曲线多为廓清型[76.00%(19/25)、80.95%(17/21)和77.78%(14/18)],LuminalA型多为平台型[82.46%(47/57)];HER-2过表达型、Luminal B型和三阴性型多有伴随征象[80.00%(20/25)、76.19%(16/21)、66.67%(12/18)],Luminal A型49.12%(28/57)有伴随征象。乳腺癌增强MRI强化方式与分子亚型呈高度相关(C=0.737,P<0.001),时间-信号强度曲线类型与分子亚型呈中度相关(C=0.567,P<0.001)。结论乳腺癌分子亚型与MRI表现具有一定相关性,可通过MRI特征初步判断乳腺癌分子亚型。 Objective To investigate the correlation between molecular subtypes of breast cancer and MRI features. Methods MRI data of 121 patients with breast cancer confirmed by pathology were retrospectively analyzed. According to the expression of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor-2 (HER-2), the tumors were classified into HER-2 over-expressed subtype, Luminal A subtype, Luminal B subtype and tri- ple-negative subtype. MRI features of different molecular subtypes of breast cancer were observed, and the correlation be- tween molecular subtype and MRI features were analyzed. Results All the 4 molecular subtypes breast cancers mainly showed slightly hypo-intense signal on TlWI (HER-2 over-expressed: 68. 00% [-17/25], Luminal A: 66.67% [38/57], Luminal B: 76.19% [16/21], triple-negative: 55.56% [,10/18]). On enhanced MRI, HER-2 over-expressed subtype mainly displayed non-mass-like enhancement (84.00% [-21/25]), Luminal A subtype mainly displayed heterogeneous en- hancement (75.44% [43/57]), Luminal B subtype and triple-negative subtype mainly displayed ring enhancement (52.38% [,,11/21] and 83.33% [15/18]). The time-signal intensity curve mostly appeared as washout type in HER-2 o- ver-expressed subtype (76.00% [,19/25]), Luminal B (80.95% [17/213) and triple-negative subtype (77.78% [14/183), and platform type in Luminal A subtype (82.46% [47/57]). Most of HER-2 over-expressed (80.00% [,20/25]), Luminal B (76.19% [-16/21]), triple-negative subtype (66.67% [12/18]) and 49.12% (28/57) of Luminal A subtype breast canc- ers had accompanied signs. The molecular subtype was highly correlated with enhancement features (C= 0. 737, P〈 0. 001) and moderately correlated with time-signal intensity curve type (C=0. 567, P〈0. 001). Conclusion There is cor- relation between molecular subtype of breast cancer and MRI features. Molecular subtype of breast cancer can be initially predicted through MRI features.
出处 《中国介入影像与治疗学》 CSCD 2014年第8期497-501,共5页 Chinese Journal of Interventional Imaging and Therapy
关键词 乳腺肿瘤 磁共振成像 分子亚型 Breast neoplasms Magnetic resonance imaging Molecular subtypes
  • 相关文献

参考文献25

  • 1Teifke A, Hlawatsch A, Beier T, et al. Undetected malignancies of the breast: Dynamic contrast-enhanced MR imaging at 1.0T. Radiology, 2002,224(3) : 881-888.
  • 2La Trenta LR, Mcneil JH, Morris EA, et al. Breast lesions de- tected with MR imaging: Utility and histopathologic importance of identification with US. Radiology, 2003,227(3) :856-861.
  • 3<乳腺癌HER2检测指南>编写组,霍临明.乳腺癌HER2检测指南[J].中华病理学杂志,2006,35(10):631-633. 被引量:167
  • 4International Human Genome Sequencing Consortium. Finishing the euchromatic sequence of the human genome. Nature, 2004, 431(7011) :931-945.
  • 5Onitilo AA, Engel JM, Greenlee RT, et al. Breast cancer sub- types based on ER/PR and Her2 expression: Comparison of clini- copathologic features and survival. Clin Med Res, 2009,7 (1-2):4-13.
  • 6Kennecke H, Yerushalmi R, Woods R, et al. Metastatic behav- ior of breast cancer subtypes. J Clin Oncol, 2010,28(20) : 3271- 3277.
  • 7Haffty BG, Yang Q, Reiss M, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early- stage breast cancer. J Clin Oncol, 2006,24(36):5652-5657.
  • 8Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adju- vant hemotherapy for operable HER2-positive breast cancer. N Engl Jed, 2005,353(16) :1673-1684.
  • 9Perez EA, Romond EH, Suman VJ, et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epi- dermal growth factor receptor 2 positive breast cancer: Joint anal- ysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol, 2011,29(25) : 3366-3373.
  • 10Goldhirsch A, Wood WC, Coates AS, et al. Strategies for sub- types-dealing with the diversity of breast cancer: Highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oneol, 2011,22(8) : 1736-1747.

二级参考文献43

  • 1刘进康,曾纪珍,周建华.周围型肺腺、鳞癌CT征象与癌细胞核DNA含量关系的研究[J].中华放射学杂志,1996,30(1):15-19. 被引量:55
  • 2Watters AD,Going JJ,Cooke GT,et al.Chromosome 17 aneusomy is associated with poor prognostic factors in invesive breast carcinoma.Breast Cancer Res Treat,2003,77:109-114.
  • 3Bilous M,Morey A,Armes J,et al.Chromogenic in situ hybridisation testing for HER2 gene amplification in breast cancer produces highly reproducible results concordant with fluorescence in situ hybridisation and immunohistochemistry.Pathology,2006,38:120-124.
  • 4Goldhirsch A,Glick JH,Gelber RD,et al.Meeting highlights:international expert consensus on the primary therapy of early breast cancer 2005.Annals Oncol,2005,16:1569-1583.
  • 5The Center For Devices and Radiological Health (CDRH) of the Food and Drug Administration.A document of evaluation about the PathVysionTM HER-2 DNA Probe Kit of Vysis,INC.for detecting amplification of the HER-2/neu gene via fluorescence in situ hybridization (FISH) in formalin-fixed,paraffin-embedded human breast cancer tissue specimens.[2001-12-31].http://www.fda.gov/cdrh/pmapage.html.
  • 6Shak S.Overview of the trastuzumab (Hereeptin) anti-HER2monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer.Herceptin Multinational Investigator Study Group.Semin Oncol,1999,26(4 Suppl 12):71-77.
  • 7Hammock L,Lewis M,Philips,C,et al.Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization.Hum Pathol,2003,34:1043-1047.
  • 8北京市发展和改革委员会.关于公布荧光原位杂交基因检测(FISH)等新增医疗服务价格项目的通知.京发改[2006]1376号.http://www.bjpc.gov.cn/tztg/200608/t129145.btm.
  • 9Hicks DG,Tubbs RR.Assessment of the Her2 status in breast cancer by fluorescence in situ hybridization:a technical review with interpretive guidelines.Hum Pathol,2005,36:250-261.
  • 10Wang S,Hossein Saboorian H,Frenkel EP,et al.Aneusomy 17 in breast cancer:its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status.Mod Pathol,2002,15:137-145.

共引文献254

同被引文献39

引证文献6

二级引证文献41

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部